科兴制药(688136) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 360,663,523.23, representing an increase of 11.79% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 12,403,443.45, with a basic earnings per share of CNY 0.06[5]. - Operating profit for Q1 2024 was ¥15,841,847.71, a significant recovery from a loss of ¥17,131,632.71 in Q1 2023[18]. - Net profit for Q1 2024 amounted to ¥11,488,257.28, compared to a net loss of ¥9,859,490.11 in the same period last year[18]. - The company reported a basic and diluted earnings per share of ¥0.06 for Q1 2024, recovering from a loss of ¥0.04 per share in Q1 2023[19]. - Total revenue for Q1 2024 reached ¥360,663,523.23, an increase from ¥322,637,429.95 in Q1 2023, representing a growth of approximately 11.5%[17]. Cash Flow - The net cash flow from operating activities was negative CNY 6,224,291.11[5]. - In Q1 2024, the cash inflow from operating activities totaled $290.48 million, a decrease of 10% compared to $322.68 million in Q1 2023[22]. - The net cash flow from operating activities was -$6.22 million, improving from -$46.60 million in the same quarter last year[22]. - The company reported a total cash outflow from operating activities of $296.71 million, down from $369.28 million in Q1 2023[22]. - Cash inflow from investment activities was $393.45 million, up from $362.08 million in Q1 2023, primarily due to an increase in cash received from investments[22]. - The net cash flow from investment activities was -$224.08 million, an improvement from -$296.15 million year-over-year[22]. - Cash inflow from financing activities was $113.77 million, down from $158.81 million in Q1 2023[23]. - The net cash flow from financing activities was $16.59 million, a decrease from $41.55 million in the previous year[23]. - The ending cash and cash equivalents balance was $346.87 million, down from $482.27 million at the end of Q1 2023[23]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,063,870,549.81, an increase of 1.08% from the previous year[6]. - Total assets increased to ¥3,063,870,549.81 in Q1 2024, up from ¥3,031,093,090.30 in Q1 2023[16]. - Total liabilities rose to ¥1,439,998,995.98 in Q1 2024, compared to ¥1,400,297,996.60 in Q1 2023, indicating a growth of approximately 2.9%[16]. - The total current assets as of March 31, 2024, amounted to RMB 1,160,746,557.13, an increase from RMB 1,133,624,217.10 as of December 31, 2023, reflecting a growth of approximately 2.4%[14]. - The total non-current assets were reported at RMB 1,455,000,000.00, with fixed assets valued at RMB 933,578,508.87, up from RMB 804,691,512.56, reflecting an increase of approximately 16%[14]. Shareholder Information - The company reported a total of 131,778,347 shares held by its largest shareholder, accounting for 66.15% of the total shares[11]. - The second-largest shareholder, 邓学勤, holds 1,764,125 shares, representing 0.89% of the total shares[11]. - As of March 31, 2024, the "科兴生物制药股份有限公司回购专用证券账户" held 1,308,172 shares, accounting for 0.66% of the total shares[12]. - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[13]. Research and Development - Research and development expenses totaled CNY 35,207,355.05, accounting for 9.76% of revenue, a decrease of 5.31 percentage points year-on-year[6]. - Research and development expenses decreased to ¥35,207,355.05 in Q1 2024 from ¥48,607,343.41 in Q1 2023, a reduction of about 27.5%[18]. - The company has committed to deepening lean management across all business processes to enhance operational efficiency[8]. Operational Efficiency - The company achieved a significant increase in domestic sales volume, with a 26% year-on-year growth in self-owned product sales[8]. - The company reported a decrease in sales and production costs compared to the previous year, contributing to improved operational efficiency[8]. - Non-recurring gains totaled CNY 2,330,255.09, with government subsidies and asset disposal gains included[8]. - The company’s cash flow statement for Q1 2024 is currently unaudited, indicating ongoing financial assessments[20]. Other Information - The company has not disclosed any significant new strategies or product developments during this reporting period[13]. - The company paid $54.88 million to employees, a decrease from $65.72 million in Q1 2023[22]. - The company received $391 million from investment recoveries, compared to $360 million in the same period last year[22].